Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Chinese Patent Office
Accenture
Medtronic
Johnson and Johnson
Moodys
Daiichi Sankyo
Deloitte
Cantor Fitzgerald

Generated: April 21, 2018

DrugPatentWatch Database Preview

PAGITANE Drug Profile

« Back to Dashboard

Which patents cover Pagitane, and what generic alternatives are available?

Pagitane is a drug marketed by Lilly and is included in one NDA.

The generic ingredient in PAGITANE is cycrimine hydrochloride. Additional details are available on the cycrimine hydrochloride profile page.
Summary for PAGITANE
US Patents:0
Applicants:1
NDAs:1
Bulk Api Vendors: 10
Patent Applications: 32
Drug Prices:see details
DailyMed Link:PAGITANE at DailyMed
Drug patent expirations by year for PAGITANE
Synonyms for PAGITANE
.alpha.-Cyclopentyl-.alpha.-phenyl-1-piperidinepropanol hydrochloride
(+-)-cycrimine HCl
(+-)-cycrimine hydrochloride
1-cyclopentyl-1-phenyl-3-(1-piperidyl)propan-1-ol hydrochloride
1-cyclopentyl-1-phenyl-3-(piperidin-1-yl)propan-1-ol hydrochloride
1-cyclopentyl-1-phenyl-3-piperidin-1-ylpropan-1-ol hydrochloride
1-cyclopentyl-1-phenyl-3-piperidin-1-ylpropan-1-ol,hydrochlo
1-cyclopentyl-1-phenyl-3-piperidin-1-ylpropan-1-ol;hydrochloride
1-Phenyl-1-cyclopentyl-3-piperidino-1-propanol hydrochloride
1-Piperidinepropanol, alpha-cyclopentyl-alpha-phenyl-, hydrochloride
126-02-3
a-cyclopentyl-a-phenyl-1-piperidinepropanol hydrochloride
AC1L2R5Q
AC1Q3F2K
alpha-Cyclopentyl-alpha-phenyl-1-piperidinepropanol hydrochloride
AN-5605
CHEBI:59693
CHEMBL1200828
Compound 8958
Cycrimine HCl
Cycrimine hydrochloride
Cycrimine hydrochloride [USP]
EINECS 204-764-8
Lilly 08958
LS-116015
NSC 169452
NSC-169452
NSC169452
Pagitane hydrochloride
SCHEMBL1235292
WLN: T6NTJ A2XQR &- AL5TJ & GH

US Patents and Regulatory Information for PAGITANE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly PAGITANE cycrimine hydrochloride TABLET;ORAL 008951-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Lilly PAGITANE cycrimine hydrochloride TABLET;ORAL 008951-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Fuji
Deloitte
Cerilliant
Colorcon
Chubb
US Department of Justice
Daiichi Sankyo
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.